Publications - 'P'
Publications 2026 - 2050 de 2458
| Titre | DOI |
|---|---|
|
Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX plus /- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. J. Taieb; K. Le Malicot; F.Madeleine Penault-Llorca; O. Bouche; Q. Shi; S.N. Thibodeau; J. Tabernero; E. Mini; R.M. Goldberg; G. Folprecht; J.L. Van Laethem; D.J. Sargent; S.R. Alberts; P. Laurent-Puig; F.A. Sinicrope 2015 |
10.1200/jco.2015.33.15_suppl.3507 |
|
Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort J.P. Cervoni; A. Amoros; R. Banares; J.Luis Montero; G. Soriano; D. Weil; R. Moreau; M. Pavesi; T. Thevenot; V. Di Martino; E.A.S.L.C.L.I.F. Consortium 2016 |
10.1097/MEG.0000000000000676 |
|
Prognostic value of C-reactive protein in patients with cirrhosis: external validation from the CANONIC cohort J.Paul Cervoni; A. Alex; R. Moreau; V. Arroyo; R. Jalan; F. Saliba; F. Durand; J. Wendon; T. Gustot; P. Angeli; P. Gines; T. Thevenot; V. Di Martino 2014 |
|
|
Prognostic value of C-reactive protein in patients with cirrhosis: external validation from the CANONIC cohort J.Paul Cervoni; A. Alex; R. Moreau; V. Arroyo; R. Jalan; F. Saliba; F. Durand; J. Wendon; T. Gustot; P. Angeli; P. Gines; T. Thevenot; V. Di Martino 2014 |
|
|
Prognostic value of C-reactive protein levels in patients with cirrhosis V. Di Martino; C. Coutris; J.P. Cervoni; S. Dritsas; D. Weil; C. Richou; C. Vanlemmens; T. Thevenot 2015 |
10.1002/lt.24088 |
|
PROGNOSTIC VALUE OF C-REACTIVE PROTEIN LEVELS IN PATIENTS WITH CIRRHOSIS V. Di Martino; C. Coutris; J.P. Cervoni; S. Dritsas; D. Weil; T. Thevenot 2014 |
10.1016/S0168-8278(14)60611-5 |
|
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) A. Vasseur; L. Cabel; O. Tredan; M. Chevrier; C. Dubot; V. Lorgis; W. Jacot; A. Goncalves; M. Debled; C. Levy; J.M. Ferrero; C. Jouannaud; E. Luporsi; M.A. Mouret-Reynier; F. Dalenc; J. Lemonnier; A. Savignoni; M.L. Tanguy; F.C. Bidard; J.Y. Pierga 2020 |
10.1007/s10456-019-09697-7 |
|
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients L. Rambach; A. Bertaut; J. Vincent; V. Lorgis; S. Ladoire; F. Ghiringhelli 2014 |
10.3748/wjg.v20.i6.1565 |
|
Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17-MEGA (Unicancer GI-AGEO) S. Pernot; C. Badoual; M. Terme; F. Castan; E. Marcheteau; O. Bouche; J. Bennouna; E. Francois; F. Ghiringhelli; C. de la Fouchardiere; E. Samalin; J.Baptiste Bachet; C. Borg; M. Ducreux; A. Cazes; T. Stanbury; S. Gourgou; D. Malka; J. Taieb 2016 |
10.1200/JCO.2016.34.15_suppl.4030 |
|
Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply D.M. Kurtz; F. Scherer; M.C. Jin; J. Soo; A.F.M. Craig; M.S. Esfahani; J.J. Chabon; H. Stehr; C.Long Liu; R. Tibshirani; L.S. Maeda; N.K. Gupta; M.S. Khodadoust; R.H. Advani; A.M. Newman; U. Duehrsen; A. Huettmann; M. Meignan; O. Casasnovas; J.R. Westin; M. Roschewski; W.H. Wilson; G. Gaidano; D. Rossi; M. Diehn; A.A. Alizadeh 2019 |
10.1200/JCO.18.01907 |
|
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials D. Pietrasz; S. Wang-Renault; J. Taieb; L. Dahan; M. Postel; J. Durand-Labrunie; K. Le Malicot; C. Mulot; Y. Rinaldi; J.M. Phelip; S. Doat; H. Blons; A. de Reynies; J.B. Bachet; V. Taly; P. Laurent-Puig 2022 |
10.1038/s41416-021-01624-2 |
|
Prognostic Value of F-18-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers S. Masson-Deshayes; C. Schvartz; C. Dalban; S. Guendouzen; J.M. Pochart; A. Dalac; S. Fieffe; C. Bruna-Muraille; T.Sandrine Dabakuyo-Yonli; D. Papathanassiou 2015 |
|
|
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project C. Bailly; T. Carlier; A. Berriolo-Riedinger; O. Casasnovas; E. Gyan; M. Meignan; A. Moreau; B. Burroni; L. Djaileb; R. Gressin; A. Devillers; T. Lamy; C. Thieblemont; O. Hermine; F. Kraeber-Bodere; S. Le Gouill; C. Bodet-Milin 2020 |
10.3324/haematol.2019.223016 |
|
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma B. Paquette; D. Vernerey; B. Chauffert; S. Dabakuyo; L. Feuvret; L. Taillandier; D. Frappaz; H. Taillia; R. Schott; F. Ducray; M. Fabbro; I. Tennevet; F. Ghiringhelli; J.S. Guillamo; X. Durando; D. Castera; M. Frenay; C. Campello; C. Dalban; J. Skrzypski; O. Chinot; A. Anota; F. Bonnetain 2016 |
10.1002/cam4.734 |
|
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma B. Paquette; D. Vernerey; A. Anota; B. Chauffert; T.Sandrine Dabakuyo; L. Feuvret; L. Taillandier; D. Frappaz; H. Taillia; R. Schott; M. Fabbro; I. Tennevet; F. Ghiringhelli; C. Campello; C. Dalban; J. Skrzypski; O. Chinot 2015 |
|
|
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients F. Fiteni; D. Vernerey; F. Bonnetain; F. Vaylet; H. Sennelart; J. Tredaniel; D. Moro-Sibilot; D. Herman; H. Laize; P. Masson; M. Derollez; C. Clement-Duchene; B. Milleron; F. Morin; G. Zalcman; E. Quoix; V. Westeel 2016 |
10.1016/j.ejca.2015.10.004 |
|
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology M. Diouf; T. Filleron; A.L. Pointet; A.C. Dupont-Gossard; D. Malka; P. Artru; M. Gauthier; T. Lecomte; T. Aparicio; A. Thirot-Bidault; C. Lobry; F. Fein; O. Dubreuil; B. Landi; A. Zaanan; J. Taieb; F. Bonnetain 2016 |
10.1007/s11136-015-1198-x |
|
Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol D. Canioni; P. Brice; S. Bologna; L. Voillat; J. Gabarre; O. Casasnovas; A. Devidas; B. Coiffier; M. Aoudjhane; B. Audhuy; M. Andre; C. Fortpied; P. Carde; N. Mounier; J. Briere 2018 |
10.1182/blood-2018-99-118039 |
|
Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: A French sentinel node multicenter cohort study G. Houvenaeghel; J.M. Classe; J.R. Garbay; S. Giard; M. Cohen; C. Faure; C. Helene; C. Belichard; S. Uzan; D. Hudry; P. Azuar; R. Villet; F.Penault Llorca; C.Tunon de Lara; A. Goncalves; B. Esterni; M. Marc; L. Eric; J. Jocelyne; F. Jean; D. Francois; C.Marie Pierre; C.Ewald Elisabeth; G. Pierre; B. Emmanuel 2014 |
10.1016/j.breast.2014.04.004 |
|
Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial. J. Taieb; J.F. Emile; K. Le Malicot; A. Zaanan; J. Tabernero; E. Mini; P. Rougier; J.Luc Van Laethem; J.A.Res Bridgewater; G. Folprecht; R. Salazar; A. Zawadi; E. Van Cutsem; C. Lepage; P. Laurent-Puig; H. Blons 2014 |
10.1200/jco.2014.32.15_suppl.3549 |
|
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset H. Blons; J.F. Emile; K. Le Malicot; C. Julie; A. Zaanan; J. Tabernero; E. Mini; G. Folprecht; J.L. Van Laethem; J. Thaler; J. Bridgewater; L. Norgard-Petersen; E. Van Cutsem; C. Lepage; M.A. Zawadi; R. Salazar; P. Laurent-Puig; J. Taieb 2014 |
10.1093/annonc/mdu464 |
|
Prognostic value of local relapse for patients with endometrial cancer Y. Dabi; J. Uzan; S. Bendifallah; L. Ouldamer; V. Lavoue; G. Canlorbe; E. Raimond; C. Coutant; O. Graesslin; P. Collinet; A. Bricou; E. Darai; M. Ballester; B. Haddad; C. Touboul; G.Rech FRANCOGYN 2017 |
10.1016/j.ejso.2017.08.004 |
|
Prognostic value of lung membrane conductance in sickle cell disease A. Beurnier; J. Graveleau; T. Le Tourneau; A. Masseau; B. Degano; B. Ricolleau; F.X. Blanc; A. Chambellan 2018 |
10.1183/13993003.congress-2018.PA2433 |
|
Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy C. Gallois; J. Taieb; D. Le Corre; K. Le Malicot; J. Tabernero; C. Mulot; J.F. Seitz; T. Aparicio; G. Folprecht; C. Lepage; E. Mini; J.L. van Laethem; J.F. Emile; P. Laurent-Puig 2017 |
|
|
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy C. Gallois; J. Taieb; D. Le Corre; K. Le Malicot; J. Tabernero; C. Mulot; J.F. Seitz; T. Aparicio; G. Folprecht; C. Lepage; E. Mini; J.L. Van Laethem; J.F. Emile; P. Laurent-Puig; P.E.T.A.C.C.8 Investigators 2018 |
10.1158/1078-0432.CCR-18-0866 |